XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenues (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2021
USD ($)
PerformanceObligation
Component
Revenues [Abstract]      
Revenue $ 119,497 $ 130,524  
WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]      
Revenues [Abstract]      
Upfront payment received     $ 200,000
Number of material components | Component     4
Number of performance obligations | PerformanceObligation     1
Transaction price     $ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca 55.00%    
Commercial Revenue [Member]      
Revenues [Abstract]      
Revenue $ 59,593 67,768  
SPINRAZA Royalties [Member]      
Revenues [Abstract]      
Revenue 38,455 50,247  
WAINUA Royalties [Member]      
Revenues [Abstract]      
Revenue 1,125 0  
Other Commercial Revenue [Member]      
Revenues [Abstract]      
Revenue 20,013 17,521  
TEGSEDI and WAYLIVRA Revenue, Net [Member]      
Revenues [Abstract]      
Revenue 8,628 6,478  
Licensing and Other Royalty Revenue [Member]      
Revenues [Abstract]      
Revenue 11,385 11,043  
Research and Development Revenue [Member]      
Revenues [Abstract]      
Revenue 59,904 62,756  
Collaborative Agreement Revenue [Member]      
Revenues [Abstract]      
Revenue 49,345 38,334  
WAINUA Joint Development Revenue [Member]      
Revenues [Abstract]      
Revenue $ 10,559 $ 24,422